MS1-4 - A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR).

MLA

Shoji, Hirokazu, et al. “MS1-4 - A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR).” Annals of Oncology, vol. 30, Oct. 2019, p. vi45. EBSCOhost, https://doi.org/10.1093/annonc/mdz334.001.

APA

Shoji, H., Kudo-Saito, C., Takaishi, H., Takahashi, N., Denda, T., Kawakami, T., Yamaguchi, K., Furuse, J., Moriwaki, T., Takano, T., Sawada, R., Miyamoto, T., Imazeki, H., Aoki, K., Muro, K., & Boku, N. (2019). MS1-4 - A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR). Annals of Oncology, 30, vi45. https://doi.org/10.1093/annonc/mdz334.001

Chicago

Shoji, Hirokazu, Chie Kudo-Saito, Hiromasa Takaishi, Naoki Takahashi, Tadamichi Denda, Takeshi Kawakami, Kensei Yamaguchi, et al. 2019. “MS1-4 - A Biomarker Analysis of Nivolumab in Previously Treated Advanced Gastric Cancer (WJOG10417GTR).” Annals of Oncology 30 (October): vi45. doi:10.1093/annonc/mdz334.001.